← All stocks

Lilly (Eli)

LLY Net selling
CIK 0000059478 #290 in the set updated 17 Sep 2026
Bought (120 mo)
$7.76M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$110.36B
$37.93M on a plan · $0.00 straight out of an exercise
Sold at will
$110.33B
1414 of 1436 sales
Net
−$110.36B
−$110.32B against sales at will

By person

57 insiders · 1,460 transactions
395×

David A. Ricks holds 395 times base salary in stock. $671.82M of shares against $1.70M in salary for 2025.

Salary from the company's own proxy. The shares are what David A. Ricks last reported holding, valued at $1,175.10, the price Common Stock was last bought or sold at on the open market here, on 17 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
LILLY ENDOWMENT INC entity
Former 10% Shareholder
$110.26B (1334)
−$110.26B
91,881,150
9.76%
$107.97B
−27.0%
Zulueta Alfonso G
SVP & President, Lilly Int'l
$14.21M (15)
−$14.21M
56,947
0.0060%
$66.92M
+29.7%
Zakrowski Donald A
SVP, Finance, & CAO
$12.22M (26) scheduled
−$12.22M
3,163
0.0003%
$3.72M
−29.6%
Jonsson Patrik
EVP & President, LLY Int'l
$10.57M (4) scheduled
−$10.57M
54,147
0.0058%
$63.63M
+179.4%
O'Neill Myles
SVP & Pres., Mfg. Operations
$9.33M (4)
−$9.33M
81,002
0.0086%
$95.19M
−13.9%
Norton Johna
EVP, Global Quality
$7.87M (4) scheduled
−$7.87M
25,556
0.0027%
$30.03M
+80.7%
Conterno Enrique A
SVP&Pres, LillyDiab & LillyUSA
$7.22M (3)
−$7.22M
132,962
0.0141%
$156.24M
+17.1%
Mahony Susan
SVP & Pres., Lilly Oncology
$6.43M (5)
−$6.43M
43,145
0.0046%
$50.70M
−48.6%
Fry Stephen F
SVP, HR & Diversity
$5.97M (7)
−$5.97M
152,631
0.0162%
$179.36M
+165.1%
Hakim Anat
EVP, GC & Secretary
$5.95M (1) scheduled
−$5.95M
34,862
0.0037%
$40.97M
+106.6%
Yuffa Ilya
EVP&Pres, LLY USA&Global Capab
$5.08M (5) scheduled
−$5.08M
29,804
0.0032%
$35.02M
+337.5%
Harrington Michael J
Senior VP and General Counsel
$3.69M (2)
−$3.69M
169,800
0.0180%
$199.53M
+43.0%
Simmons Jeffrey N
SVP&Pres. Elanco Animal Health
$2.57M (3)
−$2.57M
135,458
0.0144%
$159.18M
+22.1%
Skovronsky Daniel
EVP, CS&PO & Pres. LRL
$2.04M (3)
$4.32M (3)
−$2.28M
160,072
0.0170%
$188.10M
Barnes Melissa S
Chief Eth/Cmpl Ofcr & SVP, ERM
$1.67M (4)
−$1.67M
34,616
0.0037%
$40.68M
+1,169%
White Anne E.
EVP & Pres, Lilly Neuroscience
$108.84K (1)
$1.72M (2)
−$1.61M
74,210
0.0079%
$87.20M
+672.8%
Shaw Christi
SVP and Pres., Lilly Bio-Meds
$1.58M (3)
−$1.58M
0
0.0000%
$0.00
Ricks David A
President, Chair, and CEO
$1.55M (2)
+$1.55M
571,715
0.0607%
$671.82M
Weems Alonzo
EVP, ERM & CECO
$1.41M (4)
−$1.41M
7,951
0.0008%
$9.34M
+57.1%
Fyrwald J Erik
Director
$1.01M (2)
+$1.01M
75,418
0.0080%
$88.62M
+22.0%
TAI JACKSON P
Director
$955.66K (6)
+$955.66K
63,524
0.0067%
$74.65M
+37.7%
Rice Derica W
EVP-Global Services and CFO
$861.09K (2)
−$861.09K
38,292
0.0041%
$45.00M
Van Naarden Jacob
EVP,Pres LLY Oncology&HdCorpBD
$647.36K (1)
+$647.36K
26,626
0.0028%
$31.29M
+621.2%
Shah Aarti S.
SVP & CIDO
$526.53K (2)
−$526.53K
31,622
0.0034%
$37.16M
+235.8%
Alvarez Ralph
Director
$500.47K (1)
+$500.47K
56,503
0.0060%
$66.40M
+45.1%
Montarce Lucas
EVP & CFO
$494.63K (1)
+$494.63K
16,258
0.0017%
$19.11M
+55.3%
Crowe Maria A
President, Mfg. Operations
$182.93K (2)
−$182.93K
113,581
0.0121%
$133.47M
+37.7%
JACKSON JAMERE
Director
$127.91K (1)
+$127.91K
9,635
0.0010%
$11.32M
+1,335%
Sulzberger Gabrielle
Director
$75.02K (1)
+$75.02K
3,004
0.0003%
$3.53M
+4,090%
Smiley Joshua L
Former Officer
$170.30K (3)
$237.60K (1)
−$67.30K
77,659
0.0082%
$91.26M
+390.6%
Runge Marschall S
Director
$49.85K (1)
+$49.85K
16,593
0.0018%
$19.50M
+152.2%
HOOVER R DAVID
Director
$35.93K (1)
+$35.93K
37,784
0.0040%
$44.40M
+13.6%
LECHLEITER JOHN C
former director
872,321
0.0927%
$1.03B
+13.9%
Lundberg Jan M
EVP,Science&Tech and Pres. LRL
198,126
0.0210%
$232.82M
+72.7%
Peterson Barton R
Sr. VP, Corp. Affairs & Comm.
108,312
0.0115%
$127.28M
+15.0%
Walsh Fionnuala M
SVP, Global Quality
107,334
0.0114%
$126.13M
+25.9%
SEIFERT KATHI P
Director
77,038
0.0082%
$90.53M
+12.1%
PRENDERGAST FRANKLYN G
Director
68,574
0.0073%
$80.58M
+4.4%
MARRAM ELLEN R
Director
56,645
0.0060%
$66.56M
+12.0%
Hernandez Edgardo
EVP & Pres., Mfg. Operations
46,957
0.0050%
$55.18M
+192.6%
ESKEW MICHAEL L
Director
45,080
0.0048%
$52.97M
+24.9%
Ashkenazi Anat
EVP & CFO
42,330
0.0045%
$49.74M
+139.2%
Mason Michael B
EVP & Pres., Lilly Diabetes
39,284
0.0042%
$46.16M
+324.7%
Pusey Leigh Ann
EVP, Corp. Affairs & Comm.
31,641
0.0034%
$37.18M
Rau Diogo
EVP & CIDO
26,230
0.0028%
$30.82M
Baicker Katherine
Director
23,503
0.0025%
$27.62M
+78.4%
Kaelin William G Jr
Director
21,837
0.0023%
$25.66M
+89.8%
LUCIANO JUAN R
Director
16,918
0.0018%
$19.88M
+1,207%
Dozier Eric
EVP, Chief People Officer
14,653
0.0016%
$17.22M
+224.6%
Custer Kenneth L.
EVP & President, Card Met Hlth
10,141
0.0011%
$11.92M
+8.3%
Walker Karen
Director
6,249
0.0007%
$7.34M
+2,282%
Bertozzi Carolyn R
Director
6,243
0.0007%
$7.34M
+3,186%
Brown Adrienne S
EVP, President LLY Imm
5,142
0.0005%
$6.04M
+38.0%
JOHNSON KIMBERLY H
Director
3,265
0.0003%
$3.84M
+4,186%
Hedley Mary Lynne
Director
2,253
0.0002%
$2.65M
+721.5%
Seymour Melissa
EVP, Global Quality
1,038
0.0001%
$1.22M
Moeller Jon R
Director
304
<0.0001%
$357.55K
+328.6%
Insider
Date
Role
Action
Shares
Price
Amount
Jonsson Patrik
17 Aug 2026
EVP & President, LLY Int'l
Sold on a plan
6,500
$1,175.10
$7.64M
Zakrowski Donald A
10 Aug 2026
SVP, Finance, & CAO
Sold on a plan
2,000
$1,185.01
$2.37M
Hakim Anat
7 Aug 2026
EVP, GC & Secretary
Sold on a plan indirect
5,000
$1,190.00
$5.95M
Yuffa Ilya
10 Jun 2026
EVP&Pres, LLY USA&Global Capab
Sold on a plan
2,500
$1,150.77
$2.88M
Zakrowski Donald A
13 Nov 2025
SVP, Finance, & CAO
Sold on a plan
1,000
$1,010.50
$1.01M
Showing 250 of 1,460 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 1,251
Amendments (4/A) skipped 25
Filings about a different issuer 22
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 22
Sales straight out of an exercise 0
Sales at will 1,414
Transactions with no price 0
Shares from compensation/vesting 4,858,552
Sales filed before the plan box existed 533
History held since 1 Sep 2016